NICE revises its decision on dapagliflozin in triple therapy

NICE has published new guidance recommending the use of dapagliflozin (Forxiga) as an option for treating type II diabetes in adults as part of a triple therapy regimen with metformin and a sulfonylurea.

This supersedes earlier guidance, published in June 2013 (Technology Appraisal Guidance TA288, recommendation 1.3), in which NICE recommended that the use of dapagliflozin as triple therapy with metformin and a sulfonylurea should be confined to clinical trials.

Dapagliflozin is available as Forxiga and as a combined tablet containing both dapagliflozin and metformin (Xigduo).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more